Valeant Pharmaceuticals has decided to restructure its operations into three...

Valeant Pharmaceuticals has decided to restructure its operations into three segments. Bausch & Lomb and most of the group's international operations will belong to the durable growth segment, which will represent about half of Valeant's total turnover. The group is also considering the disposal of some core and non-core activities ...

To continue reading this article subscribe now

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Our executive edition of Eyewear Intelligence (Regular PDF format or E-Format) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Unlimited access to ewintelligence.com - all insight, analysis and statistics available online
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation
  • Breaking news

Already an Eyewear Intelligence subscriber? Sign in here.